Nuclear Medicine and Biology
Volume 34, Issue 7 , Pages 727-728 , October 2007

After bench to bedside: the impact of disease progression, commercial opportunities and available instrumentation on clinical outcome

References 

  1. In:  Eckelman WC editors. Receptor binding radiotracers. vols. I and II:Boca Raton (Fla): CRC Press; 1982;
  2. Kelloff GJ, Krohn KA, Larson SL, et al. The progress and promise of molecular imaging probes in oncologic drug development. Clin Cancer Res. 2005;11:7967–7985
  3. Eckelman WC, Rohatagi S, Krohn KA, Vera DR. Are there lessons to be learned from drug development that will Accelerate the use of molecular imaging probes in the clinic?. Nucl Med Biol. 2005;32:657–662
  4. Hartwell L, Mankoff D, Paulovich A, et al. Cancer biomarkers: a systems approach. Nat Biotechnol. 2006;24:905–908
  5. Pieslor PC. Barriers to achieving commercial success for diagnostic and therapeutic radiopharmaceuticals. Nucl Med Biol. 2007;34:729–732
  6. Jansen F, Vanderheyden J-LB. The future of SPECT in a time of PET. Nucl Med Biol. 2007;34:733–735
  7. http://www.fda.gov/CDER/regulatory/pet/Fludeoxyglucose.htm.
  8. Hoh C. Clinical use of FDG PET. Nucl Med Biol. 2007;34:737–742
  9. http://www.nia.nih.gov/ResearchInformation/ExtramuralPrograms/NeuroscienceOfAging/Summary+%E2%80%93+PET+Working+Group.htm.
  10. Logan J, Alexoff D, Kriplani A. Simplifications in analyzing PET data: effects on outcome measures. Nucl Med Biol. 2007;34:743–756
  11. Rufini V, Calcagni ML, Baum RP. Imaging of neuroendocrine tumors. Semin Nucl Med. 2006;36:228–247
  12. Fani M, Maecke HR. The status of diagnostic and therapeutic targeting of somatostatin receptor-positive tumours. In:  Mazzi U editors. Proceedings of the Seventh International Symposium on Technetium in Chemistry and Nuclear Medicine. Padova (Italy): Servizi Grafici Editoriali snc; 2006;p. 657–664
  13. Boswell CA, Brechbiel MW. Development of radiotherapeutic and diagnostic antibodies: an inside-out view. Nucl Med Biol. 2007;34:757–778
  14. Zalutsky MR, Reardon DA, Pozzi OR, et al. Targeted alpha-particle radiotherapy with [211At]-labeled monoclonal antibodies. Nucl Med Biol. 2007;34:779–785
  15. Kung HF, Kung M-P, Wey S-P, et al. Clinical acceptance of a molecular imaging agent: a long march with TRODAT. Nucl Med Biol. 2007;34:787–789
  16. Serganova I, Ponomarev V, Blasberg R. Human reporter genes: potential use in clinical studies. 2007;34:791--807.
  17. Mathis C, Lopresti B, Klunk W. Impact of amyloid imaging on drug development in Alzheimer's disease. 2007;34:809--822.
  18. Kurdziel K. Imaging Multidrug Resistance (MDR) with 4-[18F] fluoropaclitaxel (FPAC). Nucl Med Biol. 2007;34:823–831
  19. Schiffer WK, Liebling CNB, Patel V, Dewey SL. Targeting the treatment of drug abuse with molecular imaging. Nucl Med Biol. 2007;34:833–847
  20. Wallace AM, Hoh CK, Darrah DD, et al. Sentinel lymph node mapping of breast cancer via intradermal administration of Lymphoseek. Nucl Med Biol. 2007;34:849–853
  21. Knight L, Romano JE, Bright LT, et al. Platelet binding and biodistribution of 99mTc-rBitistatin in animal species and humans. Nucl Med Biol. 2007;34:855–863
  22. Drevets WC, Thase M, Moses-Kolko E, et al. Serotonin-1A receptor imaging in recurrent depression: replication and literature review. Nucl Med Biol. 2007;34:865–877
  23. Krohn KA, O'Sullivan F, Crowley J, et al. Challenges in clinical studies with multiple imaging probes. Nucl Med Biol. 2007;34:879–885

PII: S0969-8051(07)00184-9

doi: 10.1016/j.nucmedbio.2007.07.004

Nuclear Medicine and Biology
Volume 34, Issue 7 , Pages 727-728 , October 2007

Article Tools